MEDIMMUNE TO ACHIEVE $2 BILLION IN REVENUES BY '09.

At its annual meeting of shareholders held in Gaithersburg, Maryland, MedImmune, Inc. (NASDAQ:MEDI) provided an update on its corporate progress to its investors, and reiterated its 2004 and long-range guidance issued on April 27, 2004.

During the meeting, shareholders approved all proposals outlined in MedImmune's 2004 Proxy Statement, including the reelection of the board of directors, the ratification of PricewaterhouseCoopers LLP as the company's auditors, and approval for the 2004 Stock Incentive Plan.

Commenting on MedImmune's long-range goals, Mr. Mott told shareholders: "MedImmune is committed to advancing science and medicine to help people live better lives. By focusing on this mission over the next five years, we anticipate having four Phase 3 programs underway in 2005; bringing nine new targets out of research and into clinical development over the next three years; introducing two new products to the market between 2007 and 2009; achieving $2 billion in revenues by 2009; and delivering a five-year compounded annual growth rate in earnings per share of approximately 35 percent by 2009."

About MedImmune

MedImmune is a leading biotechnology company focused on researching, developing and commercializing products to prevent or treat infectious disease, autoimmune disease and cancer. MedImmune actively markets four products, Synagis(R) (palivizumab), Ethyol(R) (amifostine), FluMist(TM) (Influenza Virus Vaccine Live, Intranasal), and CytoGam(R) (cytomegalovirus immune globulin intravenous (human)), and has additional products in clinical testing. MedImmune employs approximately 1,800 people, is headquartered in Gaithersburg, Maryland, and has additional operations in Frederick, Maryland, as well as Pennsylvania, California, the United Kingdom and the Netherlands.

For more information, visit http://www.medimmune.com or call 301/398-4035.